MedTrace Logo

A Study of SPY072 in Rheumatic Disease

NCT07148414 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2026-05-08

No results posted yet for this study

Summary

This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).

Conditions

Interventions

DRUG

SPY002-072

Experimental

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

  • Spyre Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • SKYWAY-RD Study Director · Spyre Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-21
Primary Completion
2026-10-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Czechia
  • Georgia
  • Moldova
  • Poland
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07148414 on ClinicalTrials.gov